JP6748329B1 - ソフピロニウム臭化物の結晶形態及びその製造方法 - Google Patents

ソフピロニウム臭化物の結晶形態及びその製造方法 Download PDF

Info

Publication number
JP6748329B1
JP6748329B1 JP2020089283A JP2020089283A JP6748329B1 JP 6748329 B1 JP6748329 B1 JP 6748329B1 JP 2020089283 A JP2020089283 A JP 2020089283A JP 2020089283 A JP2020089283 A JP 2020089283A JP 6748329 B1 JP6748329 B1 JP 6748329B1
Authority
JP
Japan
Prior art keywords
compound
crystal
bromide
crystalline form
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020089283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020189839A (ja
Inventor
千能 丸林
千能 丸林
将仁 渡辺
将仁 渡辺
ブリンクマン ハーバート
ブリンクマン ハーバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Priority to JP2020133620A priority Critical patent/JP7605598B2/ja
Application granted granted Critical
Publication of JP6748329B1 publication Critical patent/JP6748329B1/ja
Publication of JP2020189839A publication Critical patent/JP2020189839A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/147—Saturated compounds having only one carboxyl group and containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020089283A 2019-05-23 2020-05-22 ソフピロニウム臭化物の結晶形態及びその製造方法 Active JP6748329B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020133620A JP7605598B2 (ja) 2019-05-23 2020-08-06 ソフピロニウム臭化物の結晶形態及びその製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851880P 2019-05-23 2019-05-23
US62/851,880 2019-05-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020133620A Division JP7605598B2 (ja) 2019-05-23 2020-08-06 ソフピロニウム臭化物の結晶形態及びその製造方法

Publications (2)

Publication Number Publication Date
JP6748329B1 true JP6748329B1 (ja) 2020-08-26
JP2020189839A JP2020189839A (ja) 2020-11-26

Family

ID=72146250

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020089283A Active JP6748329B1 (ja) 2019-05-23 2020-05-22 ソフピロニウム臭化物の結晶形態及びその製造方法
JP2020133620A Active JP7605598B2 (ja) 2019-05-23 2020-08-06 ソフピロニウム臭化物の結晶形態及びその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020133620A Active JP7605598B2 (ja) 2019-05-23 2020-08-06 ソフピロニウム臭化物の結晶形態及びその製造方法

Country Status (18)

Country Link
US (3) US20220298108A1 (https=)
EP (1) EP3972955A4 (https=)
JP (2) JP6748329B1 (https=)
KR (1) KR20220011671A (https=)
CN (1) CN114008023B (https=)
AU (1) AU2020277881B2 (https=)
BR (1) BR112021023241A2 (https=)
CA (1) CA3139948A1 (https=)
CL (1) CL2021003047A1 (https=)
CO (1) CO2021017456A2 (https=)
IL (1) IL288285B1 (https=)
MX (1) MX2021014163A (https=)
MY (1) MY206154A (https=)
PH (1) PH12021552915A1 (https=)
SG (1) SG11202111678WA (https=)
TW (2) TWI838531B (https=)
WO (1) WO2020235665A1 (https=)
ZA (1) ZA202109514B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220298108A1 (en) * 2019-05-23 2022-09-22 Kaken Pharmaceutical Co., Ltd. Crystalline form of sofpironium bromide and preparation method thereof
EP4213158A1 (en) 2020-11-13 2023-07-19 Ahead Biocomputing, Co. Ltd Information processing device, information processing method, recording medium recording information processing program, and information processing system
CN115925603B (zh) * 2022-11-29 2025-07-22 山东齐都药业有限公司 索吡溴铵的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7417147B2 (en) * 2005-11-10 2008-08-26 Bodor Nicholas S Soft anticholinergic zwitterions
ATE529399T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
MX357741B (es) * 2012-07-06 2018-07-23 Laboratorios Senosiain S A De C V Star Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
US9512166B2 (en) * 2012-09-05 2016-12-06 Amri Ssci, Llc Cocrystals of progesterone
US20150259283A1 (en) * 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10282282B2 (en) * 2016-06-29 2019-05-07 Synopsys, Inc. Automated HTTP user flows simulator
EP3494106B1 (en) * 2016-08-02 2022-07-20 Journey Medical Corporation Processes for making, and methods of using, glycopyrronium compounds
US20220298108A1 (en) * 2019-05-23 2022-09-22 Kaken Pharmaceutical Co., Ltd. Crystalline form of sofpironium bromide and preparation method thereof

Also Published As

Publication number Publication date
JP2020189856A (ja) 2020-11-26
IL288285B1 (en) 2026-02-01
TW202110796A (zh) 2021-03-16
CA3139948A1 (en) 2020-11-26
SG11202111678WA (en) 2021-11-29
US20210395197A1 (en) 2021-12-23
JP2020189839A (ja) 2020-11-26
AU2020277881A1 (en) 2021-12-09
CN114008023A (zh) 2022-02-01
ZA202109514B (en) 2023-12-20
US11566000B2 (en) 2023-01-31
CL2021003047A1 (es) 2022-09-20
AU2020277881B2 (en) 2025-03-06
CO2021017456A2 (es) 2022-01-17
US11584715B2 (en) 2023-02-21
EP3972955A4 (en) 2023-07-05
TW202411205A (zh) 2024-03-16
KR20220011671A (ko) 2022-01-28
CN114008023B (zh) 2024-02-09
IL288285A (en) 2022-01-01
BR112021023241A2 (pt) 2022-01-04
TWI870116B (zh) 2025-01-11
MX2021014163A (es) 2022-01-04
TWI838531B (zh) 2024-04-11
EP3972955A1 (en) 2022-03-30
JP7605598B2 (ja) 2024-12-24
US20220298108A1 (en) 2022-09-22
PH12021552915A1 (en) 2022-04-04
MY206154A (en) 2024-12-02
WO2020235665A1 (en) 2020-11-26
US20210171460A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
AU2019280850A1 (en) Novel salts and crystals
JP6748329B1 (ja) ソフピロニウム臭化物の結晶形態及びその製造方法
JP2018520205A (ja) レンバチニブメシル酸塩の新規結晶形及びその製造方法
EP4043455A1 (en) Bicyclic compound that acts as crbn protein regulator
CA3057923A1 (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
CN102993205B (zh) 一种高收率制备高纯度西地那非游离碱的纯化方法
EP3665176B1 (en) Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
EP2536705A1 (en) Polymorphic forms of lubiprostone
EP2516412A1 (en) Processes for the purification of lubiprostone
JP2020535193A (ja) 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス
CN118047784B (zh) 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物
JP7776258B2 (ja) ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
UA79248C2 (en) Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
CN107602518B (zh) 香豆素-二硫代氨基甲酸酯衍生物及其合成方法
JP2024511614A (ja) フッ素置換ピリドピラゾール系化合物の結晶形及びその製造方法
HK40068368A (en) Crystalline form of sofpironium bromide and preparation method thereof
JP2022539342A (ja) ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法
HK40068368B (zh) 索吡溴铵的晶型及其制备方法
JP7839371B2 (ja) スピロ環含有誘導体の塩、結晶形、並びにその調製方法および使用
KR101525296B1 (ko) 라미부딘 옥살레이트 및 이의 제조방법
JP2018016569A (ja) （１ｓ）−１−［３−（ジメチルアミノ）プロピル］−１−（４−フルオロフェニル）−１，３−ジヒドロイソベンゾフラン−５−カルボニトリル蓚酸塩の製造方法
JP2011522016A (ja) ４−ブロモフェニル１，４−ジアザビシクロ［３．２．２］ノナン−４−カルボキシラートのフマル酸塩、この結晶形態、調製、および治療的使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200522

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200522

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200806

R150 Certificate of patent or registration of utility model

Ref document number: 6748329

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250